Why the study?
Tricuspid regurgitation carries a poor prognosis and high surgical mortality, driving rapid development and clinical adoption of transcatheter tricuspid therapies.
This review highlights the rapid development and current clinical status of transcatheter therapies for tricuspid regurgitation.
Transcatheter tricuspid therapies are advancing rapidly; leaves open optimal patient selection and outcomes pending randomized data.
Tricuspid regurgitation is a complex disease that carries a poor prognosis, and surgical repair is associated with high mortality. In light of the success of other transcatheter-based valve interventions, transcatheter tricuspid therapy has recently seen exponential use both clinically and in innovation. Given the rapid development of many tricuspid systems and multiple on-going clinical trials, the aim of this review is to highlight the current state of transcatheter tricuspid therapeutics and to provide an up-to-date view of their clinical use, outcomes and future directions.
No takes yet. Share an insight, caveat, or question.
Romeo et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: